Clinical Trial Update: The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating ruxolitinib versus best available therapy in high-risk essential thrombocythemia in second-line treatment was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Essential Thrombocythemia | Phase 2, Phase 3 | Status: TERMINATED